Clinical Trials Sponsored by PeriTec Biosciences Ltd

Total 371 results

Edinburgh Biosciences Ltd
Onorach Clinical

Terminated

A Study To Assess A Novel Form Of Cataract Treatment Using The Non-Invasive LEDINBIO Proof-Of-Concept Device

Cataract

Latvia
Guangzhou Gloria Biosciences Co., Ltd.

Unknown

Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma

Classical Hodgkin's Lymphoma

China
Ikaria Bioscience Pty Ltd

Not yet recruiting

Study of RN0361 in Adult Subjects

Hypertriglyceridemia | Familial Chylomicronemia

Australia
Norroy Bioscience Co., LTD

Recruiting

Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM005 in Patients

Clear Cell Renal Cell Carcinoma Metastatic

China
SK Bioscience Co., Ltd.

Completed

Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months

Influenza

Korea, Republic of
Hangzhou Sciwind Biosciences Co., Ltd.

Recruiting

A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin

Healthy Volunteers

China
FindCure Biosciences (ZhongShan) Co., Ltd.

Recruiting

A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumors

China
Shanghai Vinnerna Biosciences Co., Ltd.

Recruiting

A Real-World Study of JT001 for COVID-19

COVID-19

China
Guangzhou Gloria Biosciences Co., Ltd.

Recruiting

Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors

Solid Tumor

China
Terran Biosciences Australia Pty Ltd

Recruiting

A Study of Idazoxan in Healthy Participants

Healthy

Australia
Suzhou Junjing BioSciences Co., Ltd.

Recruiting

AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer

Lung Cancer

China
Suzhou Abogen Biosciences Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine

COVID-19

Philippines, Pakistan, United Arab Emirates, Indonesia
Suzhou Abogen Biosciences Co., Ltd.

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1)

COVID-19

United Arab Emirates
Hangzhou Sciwind Biosciences Co., Ltd.

Completed

Phase Ia Study of XW001 in Healthy Adult Subjects

Respiratory Syncytial Virus Infections

China
Creative Biosciences (Guangzhou) Co., Ltd.

Completed

A Multicenter Clinical Trial of Stool-based DNA Testing for Early Detection of Colon Cancer in China

Neoplasms | Colorectal Neoplasms | Colorectal Cancer | Digestive System Neoplasm | Advanced Adenocarcinoma | Hyperplastic Polyp

China
Akaza Bioscience Ltd
Iqvia Pty Ltd

Not yet recruiting

TAK-242 in Patients With Acute Alcoholic Hepatitis

Acute-On-Chronic Liver Failure
Bright Minds Biosciences Pty Ltd

Not yet recruiting

BMB-101 in Epilepsy With Eyelid Myoclonia (EEM)

Jeavons Syndrome

Australia
Guangzhou Gloria Biosciences Co., Ltd.

Not yet recruiting

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Persistent, Recurrent, or Metastatic Cervical Cancer

China
Guangzhou Gloria Biosciences Co., Ltd.

Not yet recruiting

GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)

Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma | Classic Hodgkin's Lymphoma
Shanghai Vinnerna Biosciences Co., Ltd.

Recruiting

A Real-world Retrospective Study of Disease Outcomes in Non-severe COVID-19 Patient

COVID-19 Patient

China
Edinburgh Biosciences Ltd
Onorach Clinical

Recruiting

Study On The Performance And Safety Of The LEDINBIO CE Device On Visual Acuity In Subjects With Cataract

Cataract in Old Age

Lithuania, Latvia, Romania
Suzhou Junjing BioSciences Co., Ltd.

Recruiting

The Safety and Efficacy of Multiple-dose of WJ01024 in Subject With Advanced Cancer

Advanced Solid Tumors | Advanced Hematologic Malignancies

China
Guangzhou Gloria Biosciences Co., Ltd.

Recruiting

Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer (CC)

Cervical Cancer

China
Shanghai Vinnerna Biosciences Co., Ltd.

Active, not recruiting

Effect of Pharmacokinetics in Healthy Chinese Subjects

The Effects of Clarithromycin or Cyclosporine on Pharmacokinetics of Deuterium Hydrobromide Ramidvir Tablets in Healthy Chinese Subjects

China
Hangzhou Sciwind Biosciences Co., Ltd.

Active, not recruiting

A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients

Type 2 Diabetes Mellitus | T2DM

China
Guangzhou Gloria Biosciences Co., Ltd.

Completed

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Liminal BioSciences Ltd.
Syneos Health

Terminated

Single Ascending Dose Study of PBI-4547 in Healthy Subjects

Healthy Subjects

Canada
Shanghai Junshi Bioscience Co., Ltd.
CTI Clinical Trial and Consulting Services; TopAlliance Biosciences, Inc.

Withdrawn

A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies

Malignancies | Previously Treated, Advanced
Dimerix Bioscience Pty Ltd
Iqvia Pty Ltd

Completed

Safety and Effectiveness of Propagermanium in Diabetic Kidney Disease Participants Receiving Irbesartan (ACTION)

Diabetic Kidney Disease

Australia
Dimerix Bioscience Pty Ltd
Iqvia Pty Ltd

Completed

Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan (ACTION)

Focal Segmental Glomerulosclerosis

Australia
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

Advanced Urothelial Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of JS401

Hyperlipidemia

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Immunogenicity of 9MW3811 in Healthy Subjects

Idiopathic Pulmonary Fibrosis

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma

Advanced Nasopharyngeal Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Advanced Lung Cancer

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer

Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer. (CT32)

Relapsed or Metastatic Non-small Cell Lung Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers

Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China

Recurrent/Refractory Malignant Lymphoma

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma (JUPITER06)

Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).

Heterozygous Familial Hypercholesterolemia

China
Shanghai Junshi Bioscience Co., Ltd.

Terminated

Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Efficacy and Safety of MW031 in PMO Subjects

Osteoporosis, Postmenopausal

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC

Advanced Hepatocellular Carcinoma (HCC)

Italy, Poland, Singapore, United States, China, Ukraine
Shanghai Junshi Bioscience Co., Ltd.

Withdrawn

A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies

Primary Condition: Advanced Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection (JUPITER 04)

Hepatocellular Carcinoma

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors

Bone Metastases

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC

Treatment-naive Advanced Non-small Cell Lung Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer

Recurrent or Metastatic NPC

China, Taiwan, Singapore
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

To Evaluate the Efficacy and Safety of JS002 in HoFH Patients

Hyperlipemia

China

Clinical Trials Sponsored by PeriTec Biosciences Ltd

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations